Paul A Friedman - Net Worth and Insider Trading
Paul A Friedman Net Worth
The estimated net worth of Paul A Friedman is at least $295 Million dollars as of 2025-04-29. Paul A Friedman is the Director of Madrigal Pharmaceuticals Inc and owns about 841,275 shares of Madrigal Pharmaceuticals Inc (MDGL) stock worth over $279 Million. Paul A Friedman is also the Director of Incyte Corp and owns about 270,531 shares of Incyte Corp (INCY) stock worth over $16 Million. Details can be seen in Paul A Friedman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paul A Friedman has not made any transactions after 2024-04-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Paul A Friedman
Paul A Friedman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul A Friedman owns 6 companies in total, including Prelude Therapeutics Inc (PRLD) , Incyte Corp (INCY) , and Alexion Pharmaceuticals Inc (ALXN) among others .
Click here to see the complete history of Paul A Friedman’s form 4 insider trades.
Insider Ownership Summary of Paul A Friedman
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 2020-09-24 | director |
| INCY | Incyte Corp | 2019-08-06 | director & Chief Executive Officer |
| ALXN | Alexion Pharmaceuticals Inc | 2020-05-14 | director |
 | | 2024-04-08 | director & Chief Executive Officer |
| | 2014-04-10 | director |
| | 2014-05-12 | director |
Paul A Friedman Latest Holdings Summary
Paul A Friedman currently owns a total of 2 stocks. Among these stocks, Paul A Friedman owns 841,275 shares of Madrigal Pharmaceuticals Inc (MDGL) as of April 8, 2024, with a value of $279 Million and a weighting of 94.54%. Paul A Friedman also owns 270,531 shares of Incyte Corp (INCY) as of August 6, 2019, with a value of $16 Million and a weighting of 5.46%.
Latest Holdings of Paul A Friedman
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MDGL | Madrigal Pharmaceuticals Inc | 2024-04-08 | 841,275 | 331.29 | 278,705,995 |
| INCY | Incyte Corp | 2019-08-06 | 270,531 | 59.52 | 16,102,005 |
Holding Weightings of Paul A Friedman
Paul A Friedman Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul A Friedman has made a total of 2 transactions in Madrigal Pharmaceuticals Inc (MDGL) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Madrigal Pharmaceuticals Inc is the sale of 26,270 shares on April 8, 2024, which brought Paul A Friedman around $6 Million.
According to the SEC Form 4 filings, Paul A Friedman has made a total of 0 transactions in Incyte Corp (INCY) over the past 5 years. The most-recent trade in Incyte Corp is the sale of 100,000 shares on August 6, 2019, which brought Paul A Friedman around $8 Million.
Insider Trading History of Paul A Friedman
- 1
Paul A Friedman Trading Performance
GuruFocus tracks the stock performance after each of Paul A Friedman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul A Friedman is 27.76%. GuruFocus also compares Paul A Friedman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul A Friedman within 3 months outperforms 8 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paul A Friedman's insider trading performs compared to the benchmark.
Performance of Paul A Friedman
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 11.32 | | | | | |
| Relative Return to S&P 500(%) | 7.52 | | | | | |
Paul A Friedman Ownership Network
Ownership Network List of Paul A Friedman
Ownership Network Relation of Paul A Friedman
Paul A Friedman Owned Company Details
What does Prelude Therapeutics Inc do?
Who are the key executives at Prelude Therapeutics Inc?
Paul A Friedman is the director of Prelude Therapeutics Inc. Other key executives at Prelude Therapeutics Inc include director & President & CEO Krishna Vaddi , EVP & Head of Chemistry Andrew Combs , and Chief Legal Counsel & Corp Sec. Bryant David Lim .
Prelude Therapeutics Inc (PRLD) Insider Trades Summary
Over the past 18 months, Paul A Friedman made no insider transaction in Prelude Therapeutics Inc (PRLD). Other recent insider transactions involving Prelude Therapeutics Inc (PRLD) include a net purchase of 953,909 shares made by Krishna Vaddi , a net purchase of 163,075 shares made by Andrew Combs , and a net purchase of 25,000 shares made by Bryant David Lim .
In summary, during the past 3 months, insiders sold 0 shares of Prelude Therapeutics Inc (PRLD) in total and bought 932,021 shares, with a net purchase of 932,021 shares. During the past 18 months, 0 shares of Prelude Therapeutics Inc (PRLD) were sold and 1,141,984 shares were bought by its insiders, resulting in a net purchase of 1,141,984 shares.
Prelude Therapeutics Inc (PRLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Prelude Therapeutics Inc Insider Transactions
Paul A Friedman Mailing Address
Above is the net worth, insider trading, and ownership report for Paul A Friedman. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Paul A Friedman's mailing address is: Wilmington De 19803.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
